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Abstract: This study assessed how BDNF (brain-derived neurotrophic factor) and other genes
involved in its signaling influence brain structure and clinical functioning in pre-diagnosis
Huntington’s disease (HD). Parallel independent component analysis (pICA), a multivariate method
for identifying correlated patterns in multimodal datasets, was applied to gray matter concentration
(GMC) and genomic data from a sizeable PREDICT-HD prodromal cohort (N = 715). pICA identified
a genetic component highlighting NTRK2, which encodes BDNF’s TrkB receptor, that correlated
with a GMC component including supplementary motor, precentral/premotor cortex, and other
frontal areas (p < 0.001); this association appeared to be driven by participants with high or low
levels of the genetic profile. The frontal GMC profile correlated with cognitive and motor variables
(Trail Making Test A (p = 0.03); Stroop Color (p = 0.017); Stroop Interference (p = 0.04); Symbol Digit
Modalities Test (p = 0.031); Total Motor Score (p = 0.01)). A top-weighted NTRK2 variant (rs2277193)
was protectively associated with Trail Making Test B (p = 0.007); greater minor allele numbers were
linked to a better performance. These results support the idea of a protective role of NTRK2 in
prodromal HD, particularly in individuals with certain genotypes, and suggest that this gene may
influence the preservation of frontal gray matter that is important for clinical functioning.
Keywords: Huntington’s disease; brain-derived neurotrophic factor; tropomyosin receptor kinase B;
supplementary motor; independent component analysis
Brain Sci. 2018, 8, 116; doi:10.3390/brainsci8070116 www.mdpi.com/journal/brainsci
Brain Sci. 2018, 8, 116 2 of 24
1. Introduction
1.1. Huntington’s Disease
Huntington’s disease (HD) is a progressive, heritable condition characterized by chorea
(involuntary motion) as well as cognitive alterations spanning executive functioning, working memory,
olfactory and facial recognition, and emotional processing [1]. HD, along with Alzheimer’s disease
(AD) and Parkinson’s disease (PD), is a proteinopathy distinguished by regionally-selective neuronal
death and protein misfolding that manifests as expanded huntingtin in HD, Lewy bodies in PD, and
β-amyloid plaques in AD [2]. Unfortunately, across these conditions limited treatment options and no
known cures are available. However, their shared features have sparked speculation about common
underlying mechanisms, and the delayed-onset of these disorders raises the appealing possibility of
developing treatments that postpone onset indefinitely, effectively eradicating the disease.
A promising way to identify treatment targets is to characterize the earliest changes before
the onset of HD. Motor impairments associated with HD, such as dystonia and chorea, often lead
to diagnosis because their disruptiveness prompts affected individuals to seek medical attention.
However, cognitive symptoms and alterations in brain volume and morphology are already present
more than a decade before diagnosis, during a period known as the prodrome [3]. In keeping with this,
PREDICT-HD is a multi-site research study aiming to identify the earliest changes in the HD prodrome,
with the hopes of identifying targets for the earliest possible interventions [3]. PREDICT-HD has
amassed a comprehensive dataset of genomic, structural and functional magnetic resonance imaging
(MRI and fMRI), diffusion tensor imaging (DTI), cognitive and motor assays, cytosine-adenine-guanine
(CAG)-repeat information, and demographic variables from over 1449 prodromal HD and control
participants, including longitudinal data from over 900 participants.
Although there is no cure for HD, its cause is known. An abnormally large cytosine-adenine-guanine
(CAG) expansion (≥36 repeats) at an HTT exon 1 locus determines future HD development. The HTT
gene encodes huntingtin protein, which is widely expressed in the brain and central nervous system [4].
Abnormally-expanded HTT encodes mutant huntingtin (mHTT), which compromises numerous
cellular processes including endocytosis and secretion, calcium homeostasis [5], glutamatergic synaptic
functioning [6], vesicular transport [7], mitochondrial functioning [8], p53 signaling [7], apoptosis, and
transcription [9].
1.2. Effects of Multiple Genes and Variants
Both within and outside the realm of huntingtin’s interactions, several lines of evidence implicate
non-HTT factors as modulators of prodromal progression and HD onset. Moreover, the reduced
genetic complexity of HD makes it tractable to disentangle onset-protection and susceptibility factors.
HTT CAG-expansion length considerably influences age at diagnosis and can be used to estimate the
age of, or time to, HD onset. Despite strong prediction accuracy for many prodromal individuals, some
outcomes deviate from expectations. For example, one PREDICT-HD participant with 44 CAG-repeats
lacked positive diagnosis at the age of 71 years, and 13 participants with <41 repeats reached the age
of 70 years with no diagnosis. HD onset prediction (based on age and CAG-repeat number) is most
accurate in individuals with >44 repeats and increasingly variable as the repeat number decreases, and
different disease progression rates are often observed in persons with the same number of CAG-repeats.
These examples highlight the onset variability and suggest that additional genetic factors may promote
or suppress HD conversion (especially at lower CAG-repeat numbers), yet little is known about
non-HTT genetic factors that account for variability in the rapidity and severity of HD symptoms
and onset.
The influence of such factors is likely also reflected by differences in brain structure and clinical
functioning throughout the prodrome. Known polygenetic neural effects suggest that multiple genes
may modulate decline; this is in keeping with the prevailing common disease-common variant
model, which posits that the combined effects of multiple common nucleotide variants, or single
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nucleotide polymorphisms (SNPs), with weak individual effects may confer disease susceptibility
or resistance [10]. At an individual level, these polymorphisms may occur in several, sometimes
interacting genes, bestowing weak enough effects to fall below statistical thresholds and avoid
elimination via natural selection [10]. We observe similar covariance in the brain; even in disorders
with regionally concentrated damage, multiple brain regions and cell types are usually affected.
1.3. Benefits of Multivariate Methods
Interactions among multiple genes can have complex effects on disease phenotypes [10].
Univariate methods such as genome-wide association studies (GWAS) have dominated large-scale
human genetic studies, despite an inability to capture this important covariation [10,11]. Univariate
tests require tens of thousands of participants, which can be impossible to achieve in rare clinical
populations, and must correct for many statistical tests. These stringent statistical standards can result
in an overshadowing of small-to-moderate genetic effects and obscured interpretation of impacted
biological pathways, as results generally consist of a few of the most significant genes, each of which is
involved in multiple cellular processes and pathways. For these reasons, multivariate methods may be
more suitable for extensive genetic studies, especially in rare clinical populations with fewer available
study participants. Rather than assessing related points, multivariate tests find interrelated patterns
and can detect weak effects in high-dimensional data.
1.4. Parallel Independent Component Analysis (pICA)
Combined effects of nucleotide-level differences (or SNPs) on gray matter concentration (GMC)
across the brain can be assessed across the genome and in candidate genes using the multivariate
method of parallel ICA (pICA) [10,11]. Through the simultaneous analysis of multimodal data, pICA
can isolate groups of correlated SNPs into novel, maximally-independent networks that affect patterns
of GMC in a population. In other words, a person whose genome aligns with a pICA SNP profile that
is correlated with a GMC profile will also likely display a brain structure consistent with that GMC
profile. pICA has been successfully applied to other clinical populations, including schizophrenia and
Alzheimer’s disease [12,13], which share key features with HD such as delayed onset, regional and
cellular selectivity of atrophy, and cognitive abnormalities.
Like other multivariate methods, pICA is optimal for examining multi-gene interactions because
it considers the cumulative effects of changes at multiple loci, likely accounting for more variation
than the strongest changes in single genes [10]. Consequently, it requires fewer statistical tests
than univariate Genome-Wide Scanning (GWS) analyses (<30 compared to hundreds of thousands).
An additional advantage of pICA is that it permits both hypothesis-driven testing (via inclusion of
reference SNPs) and the exploration of new and unexpected patterns (disease-related or otherwise) that
connect genes and their expression to brain structure and function. These advantages allow affected
pathways and gene networks to be more thoroughly defined.
1.5. Brain-Derived Neurotrophic Factor (BDNF)-Signaling Genes (a Candidate Pathway)
Genes that interact with mHTT and are involved in mHTT-compromised processes are strong
candidate HD-progression mediators. One such target is brain-derived neurotrophic factor (BDNF).
BDNF mediates neurogenesis, and accumulating evidence suggests its importance in HD development
and onset [9,14]. BDNF co-localizes with huntingtin in 99% of pyramidal motor cortical neurons
and 75% of striatal neurons, and is necessary for healthy cortico-striatal synaptic activity and striatal
GABA-ergic medium spiny neuron (MSN) survival [9].
mHTT interferes with BDNF transcription and vesicular transport (Figure 1). (a) Huntingtin
enhances BDNF microtubule transport by binding to HAP1, which engages vesicle transport proteins.
mHTT binds too tightly to HAP1, inhibiting transport. (b) Huntingtin stimulates transcription from
the BDNF exon II promoter, which is 60% less active in cells overexpressing mHTT [9]. Like many
neuronal-gene promoters, BDNF is regulated by repressor element 1/neuron-restrictive silencer
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element (RE1/NRSE), which is modulated by RE1 silencing transcription factor/neuron-restrictive
silencer factor (REST/NRSF) [7]. REST is a neuron-specific, master gene repressor that binds to
BDNF promoter II RE1 sites and recruits a co-repressor complex that includes Sin3A and REST
co-repressor (coREST). Huntingtin indirectly sequesters REST in the cytoplasm by interacting with
HAP1 and REST-interacting LIM domain protein (RILP), which directly binds REST/NRSF to mediate
translocation to the nucleus. mHTT disrupts this complex by failing to isolate REST in the cytoplasm,
leading to its increase in the nucleus and consequent recruitment of transcriptional repressors.
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Figure 1. Mutant huntingtin (mHTT) affects (a) brain-derived neurotrophic factor (BDNF) vesicular
transport across microtubules and (b) BDNF transcription. (a) Huntingtin binds to HAP1 to recruit
vesicular transport proteins. The dynein complex is shown in yellow and the dynactin complex in
purple. Together, these proteins enable retrograde vesicular transport, which is disrupted by mHTT
binding too tightly to HAP1. (b) Huntingtin sequesters RE1 silencing transcription factor (REST) in the
cytoplasm, inhibiting its accumulation in the nucleus. If mHTT fails to sequester REST, this leads to its
nuclear buildup and consequently reduces BDNF transcription.
BDNF is particularly relevant to prodromal HD. Compared to controls, asymptomatic HD
transgenic mice have reduced striatal BDNF that is lower at higher CAG-repeat numbers, indicating a
prodromal BDNF deficit [14]. Further BDNF reduction in these mice lowers onset age and worsens
motor symptoms, correlating with brain morphology changes. Furthermore, BDNF deficiency only
modestly contributes to early-life MSN survival, yet significantly reduces MSNs (by 35%) in later life,
consistent with delayed HD onset. Interestingly, the striatum does not produce its own BDNF, but
receives ~95% from the cortex and the remainder from the substantia nigra pars compacta, amygdala,
and thalamus [14]. Thus, prodromal BDNF suggests possible early deficits in regions that supply
striatal BDNF. Given that BDNF mRNA and protein reductions are present in prodromal and diagnosed
HD and are causally related to symptom severity and HD onset, factors that interact with BDNF likely
confer additional symptom and onset variability.
1.6. The Present Study
Using parallel ICA with reference (pICAr), this study leveraged legacy imaging, genomic, and
clinical data from PREDICT-HD to investigate how SNPs in BDNF-signaling genes impact clinical
functioning and patterns of brain morphology in prodromal HD. As an expansion of the pICA results,
we assessed the effects of four individual SNPs in NTRK2 (which encodes BDNF’s TrkB receptor)
on frontal gray matter and clinical functioning. Profiles including SNPs from multiple genes were
anticipated to correlate with gray matter concentration profiles and clinical functioning with maximum
effects in BDNF-related, HD-compromised pathways.
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2. Materials and Methods
2.1. Participants
A cohort of 715 expansion-positive (≥36 CAG-repeats) prodromal PREDICT-HD participants were
included in the study (448 females and 267 males; ages 18–82 years; mean CAG-repeat number = 42.5
(SD = 2.5)). Participant data included genotyping, T1-weighted structural MR images, cognitive and
motor variables, and demographics (including age, sex, years of education, and CAG-repeat number)
from PREDICT-HD [15]. Exclusion criteria included poor genomic or imaging data quality, relatedness
to another participant, or the presence of any other central nervous system disorder or unstable medical
or psychiatric condition. All PREDICT-HD participants provided written, informed consent and were
treated in accordance with protocols approved by each participating institution’s internal review board.
Participants underwent genotyping before study enrolment, and those with more than 35 CAG-repeats
who did not meet criteria for HD diagnosis were designated as prodromal.
2.2. Data Availability
SNP data included in this study are publicly available from dbGAP (Study Accession:
phs000222.v4.p2). Other PREDICT-HD data, including baseline T1-weighted MR images (used as input
files in this study), subcortical and cortical segmentations, and longitudinal clinical measurements, are
available on the public download site (ftp://ftp.ncbi.nlm.nih.gov/dbgap/studies/phs000222). Release
of the specific genetic and imaging component data generated in this study is forthcoming; however,
similar ICA-generated gray matter imaging components from a different PREDICT-HD study by the
lead author have been made available in the latest study version (Study Accession: phs000222.v5.p2;
Dataset Name: SBM_sMRI; Dataset Accession: pht006857.v1.p2). Access to the specific component
data from the study may be requested from the corresponding author.
2.3. Cognitive and Motor Variables
Seven clinical variables were selected and tested for brain structural and genetic associations
(outlined below), based on their established clinical reliability and sensitivity to prodromal HD
progression [16]. Because we were interested in genetic and brain-structural effects on cognitive
and motor functioning, we analyzed the portions of the Unified Huntington’s Disease Rating Scale
(UHDRS) relevant to these domains. The UHDRS includes four sections measuring movement,
cognition, behavior, and functional capacity. We assessed the Total Motor Score (UHDRS-TMS), which
comprises the movement portion of the UHDRS and is a sum of the scores on the individual motor
variables (oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability). We also
analyzed the Symbol Digit Modalities Test (SDMT) and the Stroop test (color, word, and interference
conditions), which are two of the three parts of the UHDRS cognition section (we did not assess
verbal fluency). In addition to the UHDRS-TMS, SDMT, and Stroop Interference, we also analyzed
Trail-Making Tests A and B (TMTA and TMTB), which are not part of the UHDRS. We chose these tests
because of our specific interest in cognition and motor functioning, and because previous work by
the PREDICT-HD group demonstrated that these measures are particularly sensitive to prodromal
changes in brain structure [16].
Briefly, the SDMT measures working memory, complex scanning, and processing speed, and is
an adaptation of the Wechsler Digit Symbol subtest [17,18]. Participants are provided with a key of
symbols paired with numbers at the top of the test page. On the same test sheet, a series of numbers
are presented in a horizontal row, and the task is to fill in the symbol matching each number in
the sequence as quickly and accurately as possible. Raw scores represent the number of correctly
completed items within 90 s; thus, higher scores indicate better performance [19].
The Stroop Color and Word Test consists of three 45-s conditions that measure basic attention
and inhibition of an overlearned response [20,21]. For the color condition, the task is to identify colors
presented on stimulus cards. For the word condition, the task is to read color names presented in
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black ink. Both the color and word conditions measure basic attention. For the interference condition,
participants identify the ink color in which color-names are printed, rather than reading the color
name itself. For example, for the word “blue” printed in green ink, the correct response is “green.”
The interference condition measures the ability to inhibit the dominant (or automatic processing)
response, which is to read the word. For each of the three conditions, raw scores reflect the number of
correct trial responses, and higher scores thus reflect better performance.
TMTA and TMTB measure visual attention and task switching [22,23]. For TMTA, the task is to
sequentially connect a series of numbered circles (e.g., 1-2-3-4, etc.) as quickly as possible. For TMTB,
participants consecutively connect numbers and letters in ascending/alphabetical order, alternating
between numbers and letters (e.g., 1-A-2-B-3-C, etc.). For both TMTA and TMTB, raw scores reflect the
time (in seconds) taken to complete the task. Thus, higher scores reflect poorer performance.
The UHDRS-TMS assesses several indicators of motor performance spanning oculomotor function,
bradykinesia, chorea, dystonia, gait, and postural stability [1,24]. Higher scores indicate poorer
motor functioning.
2.4. Genomic Data Preprocessing
Data for 1,160,231 SNPs assayed with the Illumina Human 1M platform were downloaded
from dbGAP (Study Accession: phs000222.v4.p2). Data were filtered at a 5% missingness rate per
sample and per SNP, and SNPs with a minor allele frequency (MAF) of >0.05 were selected. After
linkage disequilibrium (LD) pruning (r2 > 0.5), the full genomic dataset consisted of 305,271 SNPs
that were included in further analyses. Only one participant per family was included in the study;
the family structure was determined using PLINK identity-by-descent analysis, where p > 0.18 indicates
relatedness (http://zzz.bwh.harvard.edu/plink/ibdibs.shtml). The top 10 multi-dimensional scaling
(MDS) factors were used to correct for population structure.
2.5. Imaging Data Collection
High-resolution anatomical MR images were collected at 33 sites using General Electric, Phillips,
and Siemens scanners with field strengths of 1.5 T (Tesla) or 3 T. The study used a standardized
acquisition protocol that was modified for each site by our MR physicist. Secondary to upgrades and
acquisition changes over the 12-year study, additional variation occurred. A total of 50 site/scanner
field strength combinations were analyzed, with at least three participants from each different MRI
scanner. Images at each site were obtained using three-dimensional (3D) T1-weighted inversion
recovery turboflash (MP-RAGE) sequences. Then, 1.5 T scans were collected using General Electric
and Siemens scanners. The Siemens protocol was constructed to be similar to the General Electric
scan parameters: GRAPPA factor, 900 ms TI (inversion time), 2530 ms TR (relaxation time), 3.09 ms TE
(excitation time), 256 mm × 256 mm field of view (FoV), 10◦ flip angle, 240 coronal slices with 1 mm
slice thickness, 256 × 128 matrix with 1/4 phase FoV, 220 Hz/pixel receiver bandwidth. Protocol
for 3 T scanners commonly involved a sagittal localizing series followed by acquisition of an axial
three-dimensional (3D) volumetric spoiled gradient recalled acquisition in a steady-state (GRASS)
sequence, using the following scan parameters: ~1 mm × 1 mm × 1.5 mm voxel size, 18 ms TR, 3 ms
TE, 24 cm FoV, 20◦ flip angle, 124 slices with 1.5 mm slice thickness, 0 mm gap, 256 × 192 matrix with
3/4 phase FoV, number of excitations (NEX) = 2.
2.6. Imaging Data Preprocessing
Images were aligned with the anterior commissure-posterior commissure (AC–PC) plane,
resampled with 1 mm isotropic voxels to correct for inhomogeneity [25], and preprocessed using
SPM8 (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). Images were segmented into gray matter,
unmodulated (to isolate GM concentration), and normalized to the same SPM8 Montreal Neurological
Institute (MNI) template. Voxels were re-sliced to 2 × 2 × 2 mm3, and images were smoothed by
a 10 × 10 × 10 mm3 full-width-half-maximum (FWHM) Gaussian kernel. Processed images were
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90 × 109 × 91 voxels in size. A linear regression model was applied to each GM voxel to account
for the effects of age, sex, and site (inclusive of field strength); the site variable was coded using
49 dummy variables.
2.7. Parallel ICA with Reference (pICAr)
Prodromal GMC and SNP patterns were identified and tested for correlations by applying pICAr
to the GMC imaging and the genomic data. SNPs within nine genes implicated in BDNF-signaling
were included as references: BDNF, NGFR, NTRK2, RCOR1, SIN3A, SORT1, HAP1, REST, and RILP
(see Table 1). SNPs within 20 kbp of these genes were also included to capture regulatory elements in
intronic and intergenic regions.
Table 1. Genes from which available single nucleotide polymorphisms (SNPs) were included as
references for parallel independent component analysis with reference (pICAr).
Factor Gene(s) pICA ReferenceSNPs (#) Full Name Function
REST/NRSF
REST,
RCOR1,
RCOR3 †
4
RE1 silencing transcription
factor/neuron-restrictive
silencer factor
Transcriptional repression
Sin3A SIN3A 2 SIN3 transcription regulator familymember A
Part of co-repressor complex with
REST and coREST
CoREST RCOR1 9 REST co-repressor Part of co-repressor complex withREST and Sin3A
HAP1 HAP1 7 Huntingtin-associated protein 1
Binds to huntingtin, facilitates
brain-derived neurotrophic factor
(BDNF) transcription and transport
TrkB NTRK2 52 Tropomyosin receptor kinase B BDNF high-affinity receptor
P75 NGFR 26 Low-affinity nerve growthfactor receptor BDNF low-affinity receptor
RILP RILP 5 REST-interacting LIM domain protein REST nuclear receptor
Sortilin SORT1 12 Sortilin 1 Suggested apoptotic function withp75 and pro-BDNF
BDNF BDNF 6 Brain-derived neurotrophic factor Neuronal growth, survival,differentiation
† SNPs from this gene were not available. # = number.
PICA is an extension of ICA, a robust and popular method for isolating maximally
independent sources from a mixed signal [10,11,26]. In a general ICA model, X = AS: X is an
observation (i.e., subject-by-variable matrix); S is a statistically independent component matrix
(component-by-variables); and A is the loading coefficient or mixing matrix, the representation of
each component in the subject or sample (subject-by-component). PICA performs this extraction
simultaneously on two modalities, X1 and X2. For this experiment, X1 was a participants-by-voxels
matrix of the masked GMC images, and X2 was a participants-by-loci matrix of the 305,271 SNPs.
pICAr decomposes the observation into maximally independent sources (component matrices S1 and
S2) by updating W1 and W2 (unmixing matrices) to optimize F1 (Infomax algorithm that maximizes
the independence of modality-1 components), F2 (modified Infomax that optimizes the modality-2
component independence AND similarity to the reference matrix), and F3 (maximizes the correlations
between the two modalities’ loading coefficient matrices, A1 and A2) [10,11]. Each reference is a vector
containing alleles of a gene likely to be in linkage disequilibrium, meaning they co-occur more or
less frequently than expected for independent loci. A reference vector for each gene listed in Table 1
comprises the reference matrix r. pICA outputs a loading coefficient for each participant for each SNP
and imaging profile, representing how much the participant’s genome and brain structure matches
each profile detected in the sample.
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Xd = AdSd → Sd = WdXd, Ad = W−1d , d = 1, 2
Yd = 11+e−Ud , Ud = WdXd + Wd0
(1)
F1 = max{H(Y1)} = max
{−E[ln fy1(Y1)]} (2)
F2 = max
{
λH(Y2) + (1− λ)
[
−dist2
(
r˜,
∣∣∣S˜2k∣∣∣)]}
= max
{
λ
(−E[ln fy2(Y2)])+ (1− λ)(−‖ ∣∣∣W2kX˜2∣∣∣− r˜ ‖2
2
)} (3)
F3 = max
{
∑
i,j
Corr2(A1i, A2i)
}
= max
{
∑
i,j
Cov2(A1i, A2i)
Var(A1i)Var(A2i)
}
(4)
2.8. SNP and GMC Correlations with Clinical Variables
We then queried SNPs of interest (i.e., SNPs within Table 1 BDNF-signaling genes that were also
highlighted in the pICA results) for correlations with the cognitive and motor variables. Five SNPs
in NTRK2 were tested in separate multivariate general linear model (GLM) tests using SPSS [27];
the clinical measures were dependent variables, and the SNP value (a continuous variable between
0 and 2) was a covariate. We similarly examined associations between the clinical variables and a
pICA SNP and GMC component that were significantly correlated with each other. Here, the clinical
measures were the dependent variables and the SNP or GMC loading coefficient was a covariate.
2.9. Associations of Top-Weighted Component SNPs with Clinical Variables
To test whether the observed effects were explained by the entire component cumulatively or were
largely the effect of heavily-weighted SNPs, restricted genetic coefficients based on the most important
SNPs in the component were calculated. First, the distribution of the weights for the 305,271 SNPs in
the SNP component was fitted to a logistic distribution. Based on this, SNPs with weights more than
4.25 standard deviations (SDs) from the mean were selected as top contributing SNPs (N = 61). Weights
for these 61 SNPs within the component (61 × 1 matrix) were multiplied by participant genotypes
for these SNPs (715 × 61 matrix) to yield new participant loadings for the top 61 contributing SNPs.
These new loadings were correlated with loadings for the full component at r(713) = 0.77 (two-tailed
significance of p < 0.001). A list of the top 61 SNPs, associated genes, and weights in the component is
available in Supplementary Materials Table S1.
2.10. Confirmation of Significant Results
Permutation testing and leave-N-subjects-out (10-fold, 10% of total sample) cross-validation were
used to verify significant pICA component correlations [10,28]. Permutation testing involves a random
shuffling/mismatching of participant SNP and GMC data, which are then subjected to pICA and
correlation testing. The permutation testing is performed multiple (in this case, 1000) times, allowing
a null distribution to be formed that reveals the likelihood of obtaining the significant GMC-SNP
correlation by chance. Leave-N-out (or 10-fold validation) is achieved by running pICA on 10 separate
datasets, each containing 90% of the full data, to determine if the results from the original analysis
are replicable.
2.11. Regression Influence Plot
An influence matrix was generated using the regression influence plot function in R [29,30]
to pinpoint any individuals disproportionately driving the outcome of the significant GMC-SNP
component correlation. This function outputs a plot of studentized residuals by hat values as well as a
data frame containing hat values, studentized residuals, and Cook’s distances. The approach efficiently
describes the influence that each dependent variable value has on each fitted or predicted value.
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3. Results
3.1. pICAr
In our PREDICT-HD prodromal cohort, pICAr detected a significantly correlated GMC-SNP
component pair (r(713) = 0.17, p < 0.001). This association remained significant after Bonferroni
correction for multiple testing. The GMC component most strongly represented supplementary motor,
superior, mid, and medial frontal, and precentral/primary motor regions (Figure 2). The correlated
SNP component had strong contributions from the NTRK2 gene, which encodes BDNF’s high-affinity
receptor type (TrkB) (Figure 3). Four intronic NTRK2 SNPs (rs11140810, rs4877289, rs10868241,
rs2277193) were among the top 10 SNPs contributing to the component. Other top genes included
CDK14, FAM114A1, and HEATR4 (Table 2).
Brain Sci. 2018, 8, x FOR PEER REVIEW  9 of 24 
In our PREDICT-HD prodromal cohort, pICAr detected a significantly correlated GMC-SNP 
component pair (r(713) = 0.17, p < 0.001). This association remained significant after Bonferroni 
correction for multiple testing. The GMC component most strongly repre ented supplementary 
otor, superior, mid, and medial frontal, and precentral/primary motor regions (Figure 2). The 
correlated SNP component had strong contributions from the NTRK2 gene, which encodes BDNF’s 
high-affinity receptor type (TrkB) (Figure 3). Four intronic NTRK2 SNPs (rs11140810, rs4877289, 
rs10868241, rs2277193) were among the top 10 SNPs contributing to the component. Other top genes 
included CDK14, FAM114A1, and HEATR4 (Table 2). 
 
Figure 2. The frontal gray matter concentration (GMC) component significantly paired with the 
NTRK2 SNP component in pICAr: (a) maximum effects in right premotor and supplementary motor. 
Crosshairs are positioned at the global maximum (T(1) = 30.75) and reach a threshold at p = 0.05; (b) 
multi-slice axial topography (threshold: Z = 2.5) showing a mostly positive component with strong 
representation from superior frontal gray matter and Brodmann area 6 (supplementary and premotor 
cortex). Images are displayed using xjView (a; http://www.alivelearn.net/xjview) and Fusion ICA 
Toolbox (b; http://mialab.mrn.org/software/fit). 
 
Figure 3. Manhattan plot showing top-weighted SNPs within the SNP component that correlated with 
a frontal/supplementary motor gray matter profile in parallel ICA. The top 10 SNPs contributing to 
the component are highlighted in green, and the four top NTRK2 SNPs are circled in red. The Y axis 
indicates each SNP’s weight, or contribution, to the SNP component. The plot was generated using 
the qqman package in R version 3.4.1. 
Figure 2. The frontal gray matter concentration (GMC) component significantly paired with the
NTRK2 SNP component in pICAr: (a) maximum effects in right pr motor and supplementary motor.
Crosshairs are pos tioned at the globa maximum (T(1) = 30.75) and reach a threshold at p = 0.05;
(b) multi-slice axial topography (threshold: Z = 2.5) showing a mostly positive component with strong
representation from superior frontal gray matter and Brodmann area 6 (supplementary and premotor
cortex). Images are displayed using xjView (a; http://www.alivelearn.net/xjview) and Fusion ICA
Toolbox (b; http://mialab.mrn.org/software/fit).
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Figure 3. Manhattan plot showing top-weighted SNPs within the SNP component that correlated with
a frontal/supplementary motor gray matter profile in parallel ICA. The top 10 SNPs contributing to
the component are highlighted in green, and the four top NTRK2 SNPs are circled in red. The Y axis
indicates each SNP’s wei ht, or contribution, to the SNP component. The plot was generated using the
qqman package in R version 3.4.1.
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Table 2. The 10 SNPs most heavily weighted in the SNP component, with reference SNP cluster IDs
(rs IDs), weights in the component and their directions, associated genes, minor allele frequencies,
and variant class. SNV = single nucleotide variation, DIV = deletion/insertion variation.
SNP Weight (||) +/− Ranking Gene Minor Allele Frequency Class
rs7801922 1.29 + 1 CDK14 T = 0.34/1704 (1000 Genomes)T = 0.38/11000 (TOPMED) SNV
rs11140810 1.20 + 2 NTRK2 G = 0.42/2104 (1000 Genomes)G = 0.42/12329 (TOPMED) SNV
rs4877289 1.08 + 3 NTRK2 G = 0.38/1926 (1000 Genomes)G = 0.38/11160 (TOPMED) SNV
rs548321 1.03 + 4 70 kb 5′ of LRRC55 G = 0.41/2055 (1000 Genomes)G = 0.38/11140 (TOPMED) SNV
rs112140519 1.01 + 5 53 kb 3′ of NUS1 -=0.33/1652 (1000 Genomes) DIV
rs427790 1.00 + 6 MIR181A1,NR5A2
C = 0.33/1658 (1000 Genomes)
C = 0.38/10948 (TOPMED) SNV
rs10868241 1.0 + 7 NTRK2 A = 0.32/1614 (1000 Genomes)A = 0.24/6986 (TOPMED) SNV
rs7655305 0.99 + 8 FAM114A1 G = 0.43/2140 (1000 Genomes)G = 0.43/12519 (TOPMED) SNV
rs2277193 0.98 + 9 NTRK2 C = 0.34/1679 (1000 Genomes)C = 0.41/11827 (TOPMED) SNV
rs8012614 0.98 + 10 HEATR4 C = 0.29/1442 (1000 Genomes)C = 0.37/10860 (TOPMED) SNV
3.2. SNP and GMC Correlations with Clinical Variables
The frontal GMC component highlighted by pICA (and associated with the NTRK2 SNP
component) was significantly correlated with four of the seven queried clinical variables, including
UHDRS total motor score (F(1,672) = 6.8, p = 0.009, surviving Bonferroni multiple testing correction),
TMTA (F(1,672) = 6.3, p = 0.01, passing Bonferroni), Stroop Color (F(1,672) = 4.7, p = 0.03), and Stroop
Interference (F(1,672) = 3.8, p = 0.05). This component also approached a significant correlation with
the other three clinical variables (SDMT: F(1,672) = 3.5, p = 0.06; Stroop Total: F(1,672) = 3.4, p = 0.07;
TMTB: F(1,672) = 3.1, p = 0.08)). In each case, a higher GMC was linked to improved performance.
The frontal-GMC-associated NTRK2 SNP component was not significantly related to the clinical
measures. However, one of the top NTRK2 SNPs contributing to the component (rs2277193) was
significantly associated with TMTB (F(1,672) = 6.7, p = 0.01), an effect that survived Bonferroni
correction. Here, the minor allele was associated with better TMTB performance. This SNP also
approached a significant correlation with Stroop Interference (F(1,672) = 3.6, p = 0.058), with the minor
allele similarly being associated with better performance. NTRK2 SNP rs111408010 was also correlated
with UHDRS-TMS (F(1,672) = 3.7, p = 0.05), with a greater minor allele number being associated with
better functioning (lower TMS score), but this effect did not withstand multiple testing correction.
3.3. Confirmation of Significant Results
The pICA results passed permutation testing; the ratio of correlation values above maximally
linked components was 0.013, translating to about a 1% likelihood that the results were obtained by
chance. However, the results did not replicate in all the 10-fold validation runs, likely because the
GMC-SNP component correlation was driven by several individuals with high or low levels of the SNP
component (Figure 4). The visual interpretation was confirmed by the regression influence analysis,
which highlighted 25 participants that dominated the association (Supplementary Materials Figure S1).
All of these participants had SNP component values 2–4 SDs above or below the mean.
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3.4. Associations of Top-Weighted Component SNPs with Clinical Variables
Similar to tests with the full SNP component, clinical associations with weights comprised of the
top 61 component SNPs yielded no significant results. Derived p and r2 values re slightly weaker
for the top 61 weights but were essentially comparable.
4. Discussion
4.1. High or Low Levels of the NTRK2 SNP Profile Affect Prodromal Frontal GMC
Our results suggest that a strong or weak pres nce f the NTRK2-weighted genetic profile
may be required to significantly affect the frontal gray matter profile. The genetic effect on
frontal/supplementary motor GMC in individuals in the tail of the sample was still strong enough to
be significant and apparent within the larger sample. In keeping with this, all 25 individuals driving
the significant SNP-GMC component relationship (according to the regression influence analysis) had
SNP component scores 2–4 SDs above or below the mean; only three individuals with SNP component
values in this range were not highlighted by the regression influence test. By contrast, only six of these
participants also had GMC component values ≥2 SDs from the mean in either direction, suggesting
that the effect is specific to the SNP component. These participants did not stand out in any other
obvious way from the full prodromal sample, and represented both sexes and a variety of ages, sites,
and CAG-repeat numbers.
Four NTRK2 SNPs were among the top 10 SNPs contributing to the GMC-related SNP component.
NTRK2 (Neurotrophic Receptor Tyrosine Kinase 2) is a large (358,613 base) chromosome 9 gene located
between SLC28A3 (solute carrier family 28, sodium-coupled nucleoside transporter member 3) and
AGTPBP1 (ATP/GTP binding protein 1). NTRK2 is widely expressed in the brain (Figure 5) and
encodes BDNF’s high-affinity TrkB (tropomyosin receptor kinase B) receptor. TrkB has important
cellular functions that may underlie NTRK2’s prominence and protective role in this study.
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TrkB binds with BDNF, neurotrophin-4 (NTF4), and neurotrophin-3 (NTF3), and regulates
neuronal differentiation, growth, and survival as well as synaptic plasticity and the transcription of
cell survival genes [31]. Thus, it affects both long- and short-term learning and memory by mediating
short-term synaptic function as well as long-term potentiation. TrkB has also been implicated in
apoptosis-suppression and the promotion of communication between neurons and glial cells.
Regarding BDNF, TrkB is preferentially activated by mature BDNF and expressed in indirect
pathway striatal MSNs [9]. Following activity-dependent, anterograde transport by cortical afferents,
BDNF can act post-synaptically on TrkB receptors to inhibit GABAergic or enhance glutamatergic
synaptic transmission. By interacting with presynaptic TrkB receptors, BDNF can also be retrogradely
transported to the cell body, where it stimulates cortical glutamate release. TrkB also responds to
neuronal damage; its mRNA increases following excitotoxic lesions, and reduced TrkB is associated
with neurodegeneration in Alzheimer’s disease. In the context of HD, mHTT reduces TrkB expression
in a CAG-dependent manner (in R6/1 mice), an effect that is rescued by mHTT inactivation [9].
Like other neurotrophins, BDNF is synthesized in the endoplasmic reticulum (ER) as a large
(32 kDa) precursor protein (pro-BDNF) [9], then translocated to the Golgi complex and secretory
vesicles, proteolytically cleaved, and released as mature BDNF (14 kDa). P75, BDNF’s low-affinity
receptor (encoded by NGFR), is preferentially activated by pro-BDNF and promotes apoptosis. There
is evidence for a cortical pro-BDNF overabundance in HD, which is one explanation for the lack of
consensus on cortical BDNF reductions in HD and the prodrome [9]; pro-BDNF increases could mask
BDNF reductions when probed with methods that do not differentiate between pro- and mature BDNF.
In humans, a highly conserved and fairly common (20–30% heterozygotes, ~4% homozygotes) BDNF
polymorphism (Val66Met) in the 5′ region that encodes pro-BDNF is associated with memory deficits
and multiple disorders [14]. Mature BDNF production is not affected by Val66Met, but pro-BDNF
trafficking and packaging are substantially impacted. Interestingly, mHTT significantly blocks the
post-Golgi trafficking of Val66Val (but not Val66Met) BDNF, although neither allele is associated with
disrupted transport from the ER to the Golgi.
Considering the roles of BDNF’s high- and low-affinity receptor types in promoting cell survival
and apoptosis, respectively, a pro- to mature BDNF ratio imbalance could contribute to the abnormal
apoptosis observed in HD [14]. TrkB receptor underrepresentation could hinder BDNF’s ability to
increase its own expression. Similarly, p75 receptor or pro-BDNF overabundance could amplify
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apoptosis and contribute to disease-related decline. The results of the present study suggest that
NTRK2 variations could influence this balance protectively, promoting cell survival and preserving
frontal gray matter and cognitive and motor performance.
4.2. The SNP-GMC Component Correlation is Not an Aggregate Effect of the Entire SNP Component
Weights comprised of the top 61 SNPs contributing to the component (rather than the full
component with weights for all 305,271 SNPs) yielded comparable results when evaluated with the
GMC profile and clinical variables. Derived p and r2 values were only slightly weaker in analyses
using the top 61 SNP weights, indicating that the original results do not reflect the aggregate effects of
the entire SNP component but are rather primarily due to the top contributing SNPs.
4.3. The NTRK2-Associated Frontal Gray Matter Profile Is Related to Prodromal Cognitive and
Motor Functioning
The correlated GMC component, containing supplementary motor, superior, middle, and medial
frontal, and precentral/primary motor cortex, was significantly related to both cognitive (TMTA,
Stroop Color, Stroop Interference) and motor (TMS) performance in this cohort. Although the
variance in individual clinical performance measures accounted for by the GMC component was
small, such effects are typical when comparing single clinical variables to brain structural measures;
the observed associations were consistent with the literature reporting structural and functional
changes in these regions that correlate with altered performance on these tasks in independent
samples [32–36]. Although each of the cognitive tasks has a motor component (writing or verbalization
is required for response), the stronger correlation for TMS compared to the cognitive measures likely
reflects the strength of the supplementary and primary motor cortex in the GMC component and the
increased demand on these regions for motor relative to cognitive functioning [37]. This may also
explain why significant effects were not observed for SDMT and Stroop Word, as motor involvement
in these tasks is relatively limited.
4.4. Top Contributing NTRK2 SNPs
Among the top 10 SNPs contributing to the frontally-related SNP component were rs11140810,
rs4877289, rs10868241, and rs2277193; no other gene was represented more than once in the top 10 SNPs.
Interestingly, three of these four SNPs are between NTRK2 exons 19 and 20 (the location of an alternative
stop codon), with rs2277193 (the TMTB-related SNP) being the closest to exon 19. In fact, rs2277193 is
only 799 base pairs from rs11140810, the strongest NTRK2 contributor to the component, and it is 3577
base pairs from the other top SNP in this region (rs10868241). The placement of these SNPs (as well
as the fourth NTRK2 SNP, located between exons 16 and 17) is fitting, as truncated NTRK2 isoforms
that lack the catalytic tyrosine kinase domain (generated by alternate terminal exon 16 or exon 19) are
considered the most clinically relevant [38].
Of the NTRK2 SNPs, rs11140810 had the strongest weight in the component. The Lieber Institute
for Brain Development’s (LIBD) expression quantitative trait loci (eQTL) browser, comprised of
dorsolateral prefrontal cortex (DLPFC) expression data from 237 healthy controls and 175 schizophrenia
patients, identified this SNP as an eQTL for NTRK2 in the DLPFC at the expressed region level [39].
According to Braineac (http://www.braineac.org), an eQTL database from 134 healthy human
brains [40], the regulatory effects of rs11140810 on NTRK2 are strongest in the occipital lobe, thalamus,
and frontal cortex. Other top affected genes include SLC28A3, HNRNPK, MIR7-1, and NAA35. Table 3
lists the top component SNPs and their strongest reported regulatory effects on genes in the brain.
HaploReg, a tool for visualizing 1000 Genomes Project SNP LD information in conjunction with
Roadmap Epigenomics and ENCODE chromatin state and protein binding annotation, shows an
association of rs11140810 with markers of H3K27 acetylation (linked to active transcription) in the
brain (Table 4), as well as altered regulatory motifs including forkhead box (Foxa), glioma-associated
oncogene (GLI), hypermethylated in cancer (Hic1), and zinc finger protein (Zec) [41].
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The nearby rs2277193 had a protective effect on TMTB, in which the minor allele was associated
with improved performance. In the brain, this SNP exhibits maximum regulatory effects on many of
the same genes, albeit a less pronounced influence on NTRK2 [40]. According to Haploreg, this SNP is
associated with expression-enhancing chromatin states in the brain (Table 4), altered glucocorticoid
receptor (GR) and paired-box protein (Pax-6) regulatory motifs, and AGTPBP1 expression in the
prefrontal cortex (PFC) [41].
rs4877289 is correlated with H3K4me1 (enhancer activity associated) in anterior caudate and
cingulate gyrus, and is in strong LD with other NTRK2 SNPs associated with histone enhancement
and promotion, protein binding, altered regulatory motifs, and eQTL hits. For example, rs11140785
(LD = 0.94) bound to STAT3 in ChIP-Seq and is associated with altered myocyte enhancer factor (Mef2)
regulatory motif and expression-enhancing chromatin changes in the hippocampus, substantia nigra,
caudate, inferior temporal, cingulate gyrus, angular gyrus, and DLPFC. In the brain, this variant most
strongly affects RMI1, especially in the frontal cortex [40].
Like rs11140810, rs10868241 is an identified eQTL for NTRK2 in the DLPFC at the expressed
region level in control and disease populations [39]. It is also associated with enhancer and
promoter-associated active histone modifications in several brain regions (Table 4), and is in strong LD
with SNPs linked to enhancer histone marks and altered regulatory motifs (for example, rs4457413
(LD r2 = 0.97) is associated with alteration of 12 regulatory motifs and with histone enhancers in the
temporal lobe and PFC). In the brain, rs10868241 most strongly regulates many of the same genes as
the other top NTRK2 SNPs (SLC28A3, HNRNPK, MIR7-1, NTRK2, AGTPBP1, RMI1) [40], especially in
the frontal cortex and hippocampus.
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Table 3. Top SNPs contributing to supplementary/frontal-related pICA SNP components and reported effects on gene expression in the brain. These SNPs are
associated with gene expression changes most prominently in the frontal lobe (in agreement with the study results), thalamus, putamen, and cerebellum. The first
column lists the SNP rs ID, associated or closest gene, and gene type (I = intronic, IG = intergenic). Occ. = occipital, Thal. = thalamus, Temp. = temporal, WM = white
matter, Put = putamen, Hipp. = hippocampus, Fron. = frontal, Cereb. = cerebellum, SNigra = substantia nigra, Med. = medulla, DLPFC = dorsolateral prefrontal
cortex. † = Genes associated with more than one SNP and more than tissue type; * = Genes associated with more than one tissue type. Expression data was obtained
from Braineac [40].
SNP (rs) Occ. Thal. Temp. WM Put. Hipp. Fron. Cereb. SNigra Med. DLPFC
8012614
HEATR4 (I)
NUMB;
TMEM90A HEATR4
* ACOT4 * RBM25
*;
ACOT4 * RBM25
* RBM25 *
RBM25 *;
ACOT4 *;
HEATR4 *;
DNAL1
7801922
CDK14 (I) STEAP1
C7orf63;
STEAP2 * STEAP2
* C7orf63 * STEAP2 *
DPY19L2P4;
CDK14 * C7orf63
*
7655305
FAM114A1 (I) RPL6 PDS5A FAM114A1
* TLR6
PTTG2;
FLJ13197;
UGDH
FAM114A1 * FAM114A1 * TLR1
548321
LRRC55 (IG)
UBE2L6;
ZDHHC5 TIMM10
427790
MIR181A1,
NR5A2 (IG)
NEK7
NR5A2 *;
PTPRC;
ATP6V1G3
NR5A2 *;
MIR181A1 * MIR181A1
* MIR181A1 * NR5A2 *
11140810
NTRK2 (I) NTRK2
†
NTRK2 †;
HNRNPK †;
MIR7-1 †
NTRK2 †;
SLC28A3 † NAA35
† NTRK2 † NTRK2 † HNRNPK
†;
MIR7-1 † SLC28A3
† NTRK2 †
2277193
NTRK2 (I)
SLC28A3 †;
HNRNPK †;
MIR7-1 †
SLC28A3 † NAA35 † SLC28A3
†;
AGTPBP1 †
SLC28A3 †;
HNRNPK †;
MIR7-1 †;
NAA35 †;
AGTPBP1 †
NAA35 † SLC28A3 †
4877289
NTRK2 (I) AGTPBP1
† HNRNPK †;
MIR7-1 † SLC28A3
†
RMI1 †;
SLC28A3 †;
AGTPBP1 †
10868241
NTRK2 (I)
HNRNPK †;
MIR7-1 † SLC28A3
† RMI1 † SLC28A3 † SLC28A3
†;
NTRK2 †
HNRNPK †;
MIR7-1 †;
AGTPBP1 †
NTRK2 †
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Table 4. Genes regulated by prominent NTRK2 SNPs in this study, along with their associated functions and pathways. Sources: GeneCards human gene database [31]
and UniProt [42].
Gene Name Full Name Associated NTRK2 SNP(s) Description Type Related Pathways
SLC28A3 Solute Carrier Family 28 Member 3 rs1114081, rs2277193,rs4877289, rs10868241
Neurotransmission, vascular tone, adenosine
concentration near cell surface receptors,
transport/metabolism of nucleoside drugs
Protein coding,
nucleoside transporter
Vitamin and nucleoside transport,
thiopurine pathway,
pharmacokinetics/pharmacodynamics
AGTPBP1 ATP/GTP Binding Protein 1 rs10868241
Contains nuclear localization signals and an
ATP/GTP-binding motif, involved in the
deglutamylation of protein polyglutamate side chains,
removal of gene-encoded polyglutamates from
protein carboxy-terminus, and shortening of long
polyglutamate chains
Protein coding, zinc
carboxypeptidase,
metallocarboxypeptidase
Neuroscience
HNRNPK Heterogeneous NuclearRibonucleoprotein K
rs1114081, rs2277193,
rs4877289, rs10868241
Major pre-mRNA-binding protein, binds to poly(C)
sequences, involved in nuclear metabolism of
hnRNAs, and p53/TP53 response to DNA damage
(transcriptional activation and repression)
Protein coding,
heterogeneous nuclear
ribonucleoprotein
(hnRNP)
Translational control and mRNA splicing
MIR7-1 MicroRNA 7-1 rs1114081, rs2277193,rs4877289, rs10868241 Affiliated with an undefined RNA class RNA gene mRNA splicing, SUMOylation
NAA35 N(Alpha)-Acetyltransferase 35,NatC Auxiliary Subunit rs1114081, rs2277193
Involved in the regulation of apoptosis, and the
proliferation of smooth muscle cells Protein coding
Golgi-to-endoplasmic reticulum (ER),
trans-Golgi-network retrograde transport
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In summary, the four NTRK2 SNPs that contributed most to the SNP component were situated near
alternative stop codons (rs4877289 between exons 16 and 17, and the others between exons 19 and 20);
these SNPs act on NTRK2, its neighboring SLC28A3 and AGTPBP1 genes, and other genes (HNRNPK,
MIR7-1, NAA35, RM1) in and outside of the brain tissue. These genes are implicated in apoptosis
regulation, smooth muscle cell proliferation, mRNA splicing, neurotransmission, translational control,
SUMOylation, Golgi and ER retrograde transport, and the shortening of long polyglutamate chains,
among other functions (Table 4). The effects of these NTRK2 SNPs on genes are most common
and pronounced in the frontal cortex (in keeping with the SNP component’s connection to frontal
gray matter), followed by the thalamus, putamen, and cerebellum. Table 5 summarizes histone
modifications and altered regulatory motifs associated with these SNPs.
Table 5. Histone modifications contributing to chromatin states in the top NTRK2 SNPs in the
brain. Altered regulatory motifs associated with SNPs are also listed. H3K27ac = enhancer/
promoter-associated, H3K4me1 = enhancer-associated. CG = cingulate gyrus, IT = inferior temporal,
AG = angular gyrus, DLPFC = dorsolateral prefrontal cortex, Ant. Caud. = anterior caudate,
MHipp = middle hippocampus, SNigra = substantia nigra. Data from HaploReg v4.1 [41].
NTRK2
SNP CG IT AG DLPFC
Ant.
Caud. MHipp SNigra
Regulatory
Motifs Altered
rs11140810 H3K27ac H3K27ac H3K27ac H3K27ac Foxa, GLI, Hic1,Zec
rs4877289 H3K4me1 H3K4me1
rs10868241 H3K27ac,H3K4me1
H3K27ac,
H3K4me1 H3K27ac
H3K27ac,
H3K4me1 H3K27ac
H3K27ac,
H3K4me1
H3K27ac,
H3K4me1
rs2277193 H3K27ac H3K27ac H3K27ac H3K27ac GR, Pax-6
It is important to consider LD pruning when interpreting these results. Although two of these
SNPs (rs1114081 and rs2277193) are not in high LD with other SNPs, rs4877289 is in high LD with
three SNPs (rs10780691, rs10868235, rs10868230; r2: 0.92–0.98) and rs10868241 is in high LD with nine
SNPs (rs7858707, rs10116596, rs10122796, rs7030319, rs4329345, rs11464614, rs10780693, rs11140813,
rs4457413; r2: 0.97–1.0). Thus, the effects of the latter two SNPs in this study may be attributable to an
SNP in high LD that was pruned from the dataset.
4.5. Top Contributing SNPs Outside of NTRK2
Although NTRK2 SNPs were disproportionally represented in the top component SNPs, other
top SNPs included intronic CDK14, FAM114A1, and HEATR4 SNPs, as well as intergenic SNPs
(rs548321 closest to LRRC55, rs427790 between MIR181A1 and NR5A2). Many of these genes are
implicated in cancer regulation (Supplementary Materials Table S2). Overall, compared to top
component NTRK2 SNPs, top SNPs outside of NTRK2 were less commonly associated with histone
modifications in the brain, but were more often reported to influence regulatory motifs and gene
expression outside the brain. In Braineac data, the 10 strongest SNP influences on brain gene expression
among our top 10 component SNPs were exhibited by three of the SNPs outside of NTRK2 (rs7655305,
rs8012614, rs548321); rs7655305 accounted for half of these effects. Supplementary Materials Table
S3, a complement to Table 5, summarizes brain histone modifications and altered regulatory motifs
associated with these SNPs (the HEATR4 SNP is omitted due to the absence of relevant findings).
Of these SNPs, the intergenic SNPs rs548321 (LRRC55-associated) and rs427790 (MIR181A1 and
NR5A2-associated) share perhaps the most overlap with the NTRK2 SNPs; rs2277193 (NTRK2) and
rs548321 both alter GR (glucocorticoid receptor) and Pax (paired box) regulatory motifs (Pax-4 for
rs548321 and Pax-6 for rs2277193) and are associated with histone changes in the brain. rs11140810
(NTRK2) and rs427790 alter the same Zec transcription factor and two distinct Fox regulatory motifs
(Foxj1 for rs427790 and Foxa for rs11140810). Each of these SNPs are outlined in more detail below.
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The CDK14 variant (rs7801922) contributed to the SNP component more than any other SNP. This
intronic SNP is 68,161 bp upstream of CDK14 exon 1, and is an eQTL in the lungs (GTPBP10), tibial
artery (CDK14), tibial nerve (GTPBP10), and thyroid (DPY19L2P4) [43]. In the brain, rs7801922 is an
eQTL for the DLPFC in psychiatric populations [39]. In healthy populations, this variant most affects
genes that exhibit reduced expression in white matter relative to other brain tissue types (e.g., STEAP2,
DPY19L2P4, C7orf63) [40]. Supplementary Materials Table S4 lists examples of gene regulation related
to this SNP. rs7801922 is associated with altered regulatory motifs (ecotropic virus integration site
(Evi-1), GATA-binding factor (GATA), interferon regulatory factor (Irf), and suppressor of essential
function (SEF-1)), and is in LD with three other CDK14 SNPs associated with other regulatory motif
alterations [41].
An intronic HEATR4 (HEAT-repeat containing 4) variant was another top SNP. HEAT-repeats are
amino acid domains that often have roles in protein-protein interactions, and are considered important
for intracellular transport, microtubule dynamics, and chromosomal separation. Huntingtin is one of
the first proteins in which HEAT-repeats were discovered (HEAT stands for Huntingtin, Elongation
factor 3, protein phosphatase 2A, and TOR) [44]. The HEATR4 SNP that was prominent in our genetic
component (rs8012614) is an eQTL for ACOT4 (exon, expressed region, gene, and transcript levels),
DNAL1 (expressed region level), and HEATR4 (expressed region level) in the DLPFC [39]; in controls,
the SNP was an eQTL for ACOT4 only (exon, expressed region, and gene levels). Additionally, this
SNP has more Genotype-Tissue Expression (GTEx) eQTL hits than any other top contributing SNP,
although these are mostly outside the brain in adipose, muscle, skin, heart, pancreas, and thyroid
tissue [43]. The effect of this SNP on DNAL1 is particularly interesting, as this gene is not only part of
the Kyoto Encyclopedia of Genes and Genomes (KEGG) Huntington’s disease gene pathway but is
also directly involved in aberrant BDNF transport [45]. DNAL1 is one of three genes associated with
dynein axonemal light chain 4, part of the ATP-dependent outer dynein arms complex that acts as a
molecular motor for cilia [31].
The final intronic SNP, rs7655305, regulates the expression of FAM114A1 (mostly in the medulla,
substantia nigra, and hippocampus) [40] and other genes, especially in the cerebellum (Table 3).
This variant is an eQTL for TLR1 in the DLPFC (transcript and exon levels in the disease population) [39]
as well as other genes in many areas outside the brain, including skin (especially sun-exposed), tibial
nerve, subcutaneous and visceral adipose, breast mammary tissue, testis, thyroid, and esophagus.
rs7655305 is associated with enhancer histone marks in four tissues outside of the brain, the alteration
of CCCTC-binding factor (CTCF) and telomere length regulation (Tel2) regulatory motifs [41],
and active H3K36me3 (transcription-associated) histone modification in the middle hippocampus
(http://www.featSNP.org). This SNP is also in LD with several other intronic FAM114A1 SNPs with
correlated enhancer histone marks, altered regulatory motifs, and eQTL hits [41].
rs112140519 is a deletion/insertion variation closest to NUS1 that is linked to H3K4me3 promotion
in adipose nuclei and duodenum smooth muscle as well as the alteration of five regulatory motifs
(Dbx1, Hoxb13, Ncx, ZNF263, Zfp105) [41]. rs548321, an intergenic SNP 70 kbps from the 5′ end of
LRRC55, most strongly affects the expression of TIMM10, UBE2L6, and ZDHHC5 (especially in the
putamen, although TIMM10 effects were most prominent in the frontal cortex). Each of these genes
exhibits the lowest expression in the cerebellum relative to other brain tissue types [40]. Haploreg data
shows selective association with H3K4me1 and H3K27ac enhancements in anterior caudate, as well as
the alteration of GR and Pax-4 regulatory motifs [41]. rs427790, an intergenic SNP between MIR181A1
and NR5A2, is an eQTL hit in the testis and basal ganglia [43]. Haploreg indicates the associated
alteration of double homeodomain (Dux1), Foxj1, and Zec regulatory motifs [41].
4.6. Influence of HTT CAG-Repeats
Including the CAG-repeat number or CAG-age-product (CAP) score as a covariate did not affect
the significance of the GMC-SNP component correlation. Similarly, the inclusion of the CAP did
not nullify the significance of the NTRK2-SNP correlation with TMTB, although it did account for
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some of the variance. While we can currently only speculate on this finding, it may be attributable to
the regression of age effects from the imaging data prior to pICA. The CAP reflects the cumulative
disease burden of age and the CAG-repeat number. Because the GMC component had the effects
of age subtracted from it, CAP and CAG would be expected to display a similar relationship to the
GMC component, which is what we observed. The relationships between the GMC component and
the clinical variables, however, could be accounted for by the CAP, likely reflecting the sensitivity of
these measures to CAG and age, both of which are highly related to the clinical variables assessed in
this study.
5. Conclusions
The study results demonstrated the following:
1. In this PREDICT-HD prodromal cohort, high or low levels of an SNP profile with substantial
contributions from NTRK2 were associated with a GMC profile representing the supplementary
and primary motor cortex, as well as other frontal regions (positive correlation).
2. This frontal gray matter profile was associated with cognitive and motor performance in
this population.
3. The SNP component was not significantly associated with clinical functioning, but one of its
top NTRK2 SNPs had a protective association with performance on TMTB, a measure of task
switching and visual attention, indicating some influence on cognition.
4. Correlations between the SNP component and clinical/GMC variables were mainly due to top
contributing SNPs, rather than being an aggregate effect of the entire SNP component.
5. Top component SNPs have been associated with active histone modifications in the brain
(cingulate gyrus, inferior temporal, angular gyrus, DLPFC, caudate, hippocampus, and substantia
nigra) and altered regulatory motifs (especially the glucocorticoid receptor (GR) and zinc finger
protein (Zec)).
6. Top NTRK2 SNPs in the component were close to alternative stop codons and reportedly regulated
genes implicated in diverse functions (especially in the frontal cortex, thalamus, putamen,
and cerebellum).
Although further investigation is warranted, these results suggest that NTRK2 has protective
potential in Huntington’s disease, especially in individuals with certain genotypes. Treatments that
target BDNF receptors may help preserve frontal gray matter that is important for cognitive and
motor functioning.
6. Limitations
In any study involving many participants with a rare condition, multiple scanning sites are typical
and a certain degree of inhomogeneity in data collection is thus inevitable. This study incorporates
data from several unique 1.5 T and 3 T MRI scanners, and every effort was made to control for possible
confounds related to this. Before data collection, uniform protocols were established to ensure maximal
homogeneity of data collection. The effects of collection site and scanner field strength, as well as sex
and age, were regressed from GMC images before pICA.
Ideally, controls would be included in the analysis to permit comparisons with prodromal HD
participants. PICA was carried out with a more extensive dataset (N = 903) that included controls
(N = 189). However, the analysis did not extract a significantly correlated SNP-GMC component pair
that withstood correction for multiple testing. The effects presented in this study may be unapparent
in the combined sample with controls because they are related to other processes already aberrant in
HD, such as BDNF transcription and nuclear translocation.
Because the GMC-SNP component correlation was driven by a small percentage of participants,
the results may not apply to the entire HD population, and treatments that target NTRK2 should
consider the context of the patient’s genomic landscape. Nonetheless, for cancer and other diseases,
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emphasis is shifting away from blanket treatments toward more personalized gene therapies that
consider individual genotypes. If clinical trials to reduce mHTT are ineffective or harmful for certain
individuals in the long-run, therapies that instead target mediators of mHTT toxicity may provide a
promising alternative.
7. Future Directions
This study helped characterize the complex interactions of BDNF-signaling genes, brain structure,
and clinical functioning in prodromal HD. As genetic and epigenetic factors of prodromal HD
progression continue to be identified, potential gene therapies (such as DNA-methylating drugs and
histone-deacetylase inhibitors) can be refined, tested, and implemented more strategically [46]. To aid
the development of targeted treatments, future studies should test the validity of strong correlations
observed in the most extensive available human datasets by establishing causal links in non-human
animals. For example, many HD Drosophila (fruit fly) strains are available that permit rapid, efficient,
and inexpensive querying of SNPs and genes of interest derived from human studies. The most
promising candidates from these experiments can be flagged for continued research in mammals and
eventual use in clinical trials. A promising direction is to examine how different ratios of BDNF TrkB
and p75 receptors influence progression and onset in the context of HTT CAG-repeats. BDNF acts on
TrkB receptors to increase its own continued expression; thus, an underrepresentation of these receptors
may reduce BDNF. Similarly, p75 receptor overrepresentation or an overabundance of pro-BDNF may
promote apoptosis and contribute to disease-related decline. Another important consideration is the
impact of other BDNF exons. Huntingtin stimulates transcription from the BDNF exon II promoter,
which is 60% less active in cells overexpressing mHTT [9]. Although BDNF exon III and IV promoter
actions are not linked to huntingtin, mHTT reduces their transcription through unknown mechanisms
thought to involve cAMP Response Element Binding protein (CREB) and CREB-Binding Protein (CBP).
Thus, promoter II transcriptional reduction may be linked to huntingtin reductions, while that of
promoters III and IV may be related to mHTT toxicity. CREB and CBP are also linked to several
altered functions in HD, and their investigation is a valuable avenue for future research. This study
examined BDNF-signaling genes in relation to GMC and clinical functioning. However, white matter
is dramatically affected in HD and may also be influenced by these factors, a possibility that should be
examined in future studies. Aside from genetic influences on HD progression, epigenetic marks (which
can alter gene expression) also differ in patients compared to controls. This may be an especially
promising therapeutic direction because, unlike the fixed DNA sequence, the epigenome changes
across the lifespan and in response to environmental stimuli. Future studies should seek to characterize
prodromal epigenetic differences in various tissues, as well as identify protective and detrimental
variations in pathways with known clinical relevance to HD. An additional important future direction is
to characterize these factors longitudinally. SNP and methylation patterns, for example, in BDNF/REST
pathways may be associated with different rates of clinical decline or the rapidity of HD onset. Factors
associated with disease resilience could then be incorporated into intervention strategies to slow or
prevent HD conversion.
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